These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Wilson PW; Nam BH; Pencina M; D'Agostino RB; Benjamin EJ; O'Donnell CJ Arch Intern Med; 2005 Nov; 165(21):2473-8. PubMed ID: 16314543 [TBL] [Abstract][Full Text] [Related]
28. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Rutter MK; Meigs JB; Sullivan LM; D'Agostino RB; Wilson PW Circulation; 2004 Jul; 110(4):380-5. PubMed ID: 15262834 [TBL] [Abstract][Full Text] [Related]
29. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. Ridker PM; Hennekens CH; Buring JE; Rifai N N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371 [TBL] [Abstract][Full Text] [Related]
31. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Linnemann B; Voigt W; Nobel W; Janka HU Exp Clin Endocrinol Diabetes; 2006 Mar; 114(3):127-34. PubMed ID: 16636979 [TBL] [Abstract][Full Text] [Related]
32. C-reactive protein: a new risk assessment tool for cardiovascular disease. Clearfield MB J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491 [TBL] [Abstract][Full Text] [Related]
33. C-reactive protein: a novel marker of cardiovascular risk. Shah SH; Newby LK Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794 [TBL] [Abstract][Full Text] [Related]
34. Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome. Dupuy AM; Jaussent I; Lacroux A; Durant R; Cristol JP; Delcourt C Gerontology; 2007; 53(6):329-39. PubMed ID: 17551260 [TBL] [Abstract][Full Text] [Related]
35. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Ridker PM Circulation; 2001 Apr; 103(13):1813-8. PubMed ID: 11282915 [TBL] [Abstract][Full Text] [Related]
36. [C-reactive protein in cardiovascular risk evaluation]. Fabijanić D; Banić M; Kardum D Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418 [TBL] [Abstract][Full Text] [Related]
37. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Ridker PM Am Heart Hosp J; 2004; 2(4 Suppl 1):4-9. PubMed ID: 15539969 [TBL] [Abstract][Full Text] [Related]
38. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Yeh ET Clin Cardiol; 2005 Sep; 28(9):408-12. PubMed ID: 16250263 [TBL] [Abstract][Full Text] [Related]
39. How to use the C-reactive protein in cardiac disease? Ursella S; Mazzone M; Portale G; Testa A; Pignataro G; Covino M; Fenici P; Gasbarrini GB; Gentiloni Silveri N Minerva Cardioangiol; 2005 Feb; 53(1):59-68. PubMed ID: 15788980 [TBL] [Abstract][Full Text] [Related]
40. A Test in Context: High-Sensitivity C-Reactive Protein. Ridker PM J Am Coll Cardiol; 2016 Feb; 67(6):712-723. PubMed ID: 26868696 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]